More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics.


The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care.

More about this publication

Molecular oncology
  • Volume 17
  • Issue nr. 3
  • Pages 382-383
  • Publication date 01-03-2023

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.